Amansa Investment invests Rs 40 crore private placement in IPO bound Standard Glass Lining Technology

This transaction, amounting to Rs 40 crore, represents 1.55% of the company’s pre-offer share capital.

According to the DRHP filed in July 2024, the public issue with a face value of Rs 10 per equity share is a mix of fresh issue of shares up to Rs 250 crore and an offer for sale up to 18,444,000 equity shares Promoters and Other Selling Shareholders. In the month of October 2024, the company received Sebi’s final observation for the IPO.

Standard Glass Lining Technology offers comprehensive solutions that encompass design, engineering, manufacturing, assembly, installation, and commissioning, as well as establishing standard operating procedures for pharmaceutical and chemical manufacturers on a turnkey basis.

Its product portfolio includes essential equipment used in the production of pharmaceutical and chemical products, categorized into Reaction Systems; Storage, Separation and Drying Systems; and Plant, Engineering and Services.

As of March 31, 2024, the portfolio consisted of more than 65 products and offerings. Over the last decade, it has delivered more than 11,000 products.

The company has 443 customers, including end-users in the pharmaceutical, chemical, paint, biotechnology, and food and beverage sectors.

As of June 30, 2024, their notable customers include 30 out of approximately 80 pharmaceutical and chemical companies in the NSE 500 index. Some of its pharma clients include the likes of Aurobindo Pharma Limited, Cadila Pharmaceutical Limited, Deccan Fine Chemicals (India) Private Limited, Laurus Labs Limited, Granules India Limited, Macleods Pharmaceuticals Limited, Natco Pharma Limited, Piramal Pharma Limited, Suven Pharmaceuticals Limited, and Tagros Chemicals India Private Limited.

Standard Glass Lining Technology operates eight manufacturing facilities, covering over 400,000 square feet, strategically located in Hyderabad, Telangana, known as the “Pharma Hub” of India, which accounted for 40% of the total Indian bulk drug production in Fiscal 2024 (Source: F&S Report).

IIFL Securities Limited, and Motilal Oswal Investment Advisors Limited are the book-running lead managers, and KFin Technologies Limited is the registrar of the issue.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.